FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:912-918 March 27, 1997 Number 13 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Zimmerli, W. PubMed Citation

ABSTRACT

Background In patients with sepsis the production of arachidonic acid metabolites by cyclooxygenase increases, but the pathophysiologic role of these prostaglandins is unclear. In animal models, inhibition of cyclooxygenase by treatment with ibuprofen before the onset of sepsis reduces physiologic abnormalities and improves survival. In pilot studies of patients with sepsis, treatment with ibuprofen led to improvements in gas exchange and airway mechanics.

Methods From October 1989 to March 1995, we conducted a randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (10 mg per kilogram of body weight [maximal dose, 800 mg], given every six hours for eight doses) in 455 patients who had sepsis, defined as fever, tachycardia, tachypnea, and acute failure of at least one organ system.

Results In the ibuprofen group, but not the placebo group, there were significant declines in urinary levels of prostacyclin and thromboxane, temperature, heart rate, oxygen consumption, and lactic acidosis. With ibuprofen therapy there was no increased incidence of renal dysfunction, gastrointestinal bleeding, or other adverse events. However, treatment with ibuprofen did not reduce the incidence or duration of shock or the acute respiratory distress syndrome and did not significantly improve the rate of survival at 30 days (mortality, 37 percent with ibuprofen vs. 40 percent with placebo).

Conclusions In patients with sepsis, treatment with ibuprofen reduces levels of prostacyclin and thromboxane and decreases fever, tachycardia, oxygen consumption, and lactic acidosis, but it does not prevent the development of shock or the acute respiratory distress syndrome and does not improve survival.

Source Information

From the Divisions of Pulmonary and Critical Care Medicine (G.R.B., A.P.W., B.W.C., B.B.S.), Biostatistics (W.D.D.), and Biomedical Engineering and Computing (S.B.H.), Vanderbilt University Medical Center, Nashville; the Program of Critical Care Medicine, Department of Medicine, St. Paul's Hospital and University of British Columbia, Vancouver, B.C., Canada (J.A.R.); the University of Miami School of Medicine and Department of Veterans Affairs Medical Center, Miami (R.S.); the Department of Pulmonary and Critical Care Medicine, Louisiana State University Medical Center, New Orleans (W.R.S.); the Division of Pulmonary and Critical Care Medicine, Harborview Medical Center, University of Washington, Seattle (K.P.S.); the Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, N.C. (W.J.F.); and the Division of Pulmonary Medicine, Methodist Hospital, Indianapolis (P.E.W.).

Address reprint requests to Dr. Bernard at Rm. T-1217, Medical Center North, Vanderbilt University School of Medicine, Nashville, TN 37232.

Full Text of this Article

Related Letters:

Ibuprofen in Patients with Sepsis
Zimmerli W., Widmer A. F., Bernard G. R., Wheeler A. P., Christman B.
Extract | Full Text  
N Engl J Med 1997; 337:710, Sep 4, 1997. Correspondence

This article has been cited by other articles:

• Mayer, K., Kiessling, A., Ott, J., Schaefer, M. B., Hecker, M., Henneke, I., Schulz, R., Gunther, A., Wang, J., Wu, L., Roth, J., Seeger, W., Kang, J. X. (2009). Acute Lung Injury Is Reduced in fat-1 Mice Endogenously Synthesizing n-3 Fatty Acids. Am. J. Respir. Crit. Care Med. 179: 474-483 [Abstract] [Full Text]  
• Li Yumin, , Chen Hao, , Li Xun, , Zhou Wence, , He Minyan, , Chiriva-Internati, M., Wachtel, M.S., Frezza, E.E. (2009). A New Immunomodulatory Therapy for Severe Sepsis: Ulinastatin Plus Thymosin {alpha} 1. J Intensive Care Med 24: 47-53 [Abstract]  
• Woerndle, R. H., Maxwell, D. L. (2008). Statins and Sepsis: Good Bullet, Disappearing Target. JAOA: Journal of the American Osteopathic Association 108: 486-490 [Abstract] [Full Text]  
• Lagan, A. L., Melley, D. D., Evans, T. W., Quinlan, G. J. (2008). Pathogenesis of the systemic inflammatory syndrome and acute lung injury: role of iron mobilization and decompartmentalization. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L161-L174 [Abstract] [Full Text]  
• Wheeler, A. P. (2007). Recent Developments in the Diagnosis and Management of Severe Sepsis. Chest 132: 1967-1976 [Abstract] [Full Text]  
• Xiang, Z., Minter, R. M., Bi, X., Woolf, P. J., He, Y. (2007). miniTUBA: medical inference by network integration of temporal data using Bayesian analysis. Bioinformatics 23: 2423-2432 [Abstract] [Full Text]  
• Merx, M.W., Weber, C. (2007). Sepsis and the Heart. Circulation 116: 793-802 [Abstract] [Full Text]  
• Kellum, J. A., Kong, L., Fink, M. P., Weissfeld, L. A., Yealy, D. M., Pinsky, M. R., Fine, J., Krichevsky, A., Delude, R. L., Angus, D. C., for the GenIMS Investigators, (2007). Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 167: 1655-1663 [Abstract] [Full Text]  
• Jin, S.-W., Zhang, L., Lian, Q.-Q., Liu, D., Wu, P., Yao, S.-L., Ye, D.-Y. (2007). Posttreatment with Aspirin-Triggered Lipoxin A4 Analog Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Mice: The Role of Heme Oxygenase-1. Anesth. Analg. 104: 369-377 [Abstract] [Full Text]  
• Ryan, E. P., Malboeuf, C. M., Bernard, M., Rose, R. C., Phipps, R. P. (2006). Cyclooxygenase-2 Inhibition Attenuates Antibody Responses against Human Papillomavirus-Like Particles. J. Immunol. 177: 7811-7819 [Abstract] [Full Text]  
• Russell, J. A. (2006). Management of Sepsis. NEJM 355: 1699-1713 [Full Text]  
• Yuhki, K.-i., Kawabe, J.-i., Ushikubi, F. (2006). Role of Prostanoids in Inflammatory Tachycardia: A Reply to the Letter of Dr. Eugene Nalivaiko. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290: R1751-R1751 [Full Text]  
• Park, G. Y., Christman, J. W. (2006). Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L797-L805 [Abstract] [Full Text]  
• Vincent, J.-L., Abraham, E. (2006). The Last 100 Years of Sepsis. Am. J. Respir. Crit. Care Med. 173: 256-263 [Abstract] [Full Text]  
• Rubenfeld, G. D., Caldwell, E., Peabody, E., Weaver, J., Martin, D. P., Neff, M., Stern, E. J., Hudson, L. D. (2005). Incidence and outcomes of acute lung injury.. NEJM 353: 1685-1693 [Abstract] [Full Text]  
• Rocha, P. N., Plumb, T. J., Robinson, L. A., Spurney, R., Pisetsky, D., Koller, B. H., Coffman, T. M. (2005). Role of Thromboxane A2 in the Induction of Apoptosis of Immature Thymocytes by Lipopolysaccharide. CVI 12: 896-903 [Abstract] [Full Text]  
• Fukunaga, K., Kohli, P., Bonnans, C., Fredenburgh, L. E., Levy, B. D. (2005). Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury. J. Immunol. 174: 5033-5039 [Abstract] [Full Text]  
• Burleson, B. S., Maki, E. D. (2005). Acute Respiratory Distress Syndrome. Journal of Pharmacy Practice 18: 118-131 [Abstract]  
• Lai, C. J., Ruan, T., Kou, Y. R. (2005). The involvement of hydroxyl radical and cyclooxygenase metabolites in the activation of lung vagal sensory receptors by circulatory endotoxin in rats. J. Appl. Physiol. 98: 620-628 [Abstract] [Full Text]  
• Boffa, J.-J., Just, A., Coffman, T. M., Arendshorst, W. J. (2004). Thromboxane Receptor Mediates Renal Vasoconstriction and Contributes to Acute Renal Failure in Endotoxemic Mice. J. Am. Soc. Nephrol. 15: 2358-2365 [Abstract] [Full Text]  
• Muzaffar, S., Shukla, N., Angelini, G., Jeremy, J. Y. (2004). Nitroaspirins and Morpholinosydnonimine but Not Aspirin Inhibit the Formation of Superoxide and the Expression of gp91phox Induced by Endotoxin and Cytokines in Pig Pulmonary Artery Vascular Smooth Muscle Cells and Endothelial Cells. Circulation 110: 1140-1147 [Abstract] [Full Text]  
• Vincent, J.-L. (2004). Evidence-Based Medicine in the ICU: Important Advances and Limitations. Chest 126: 592-600 [Abstract] [Full Text]  
• Delgado, M., Pozo, D., Ganea, D. (2004). The Significance of Vasoactive Intestinal Peptide in Immunomodulation. Pharmacol. Rev. 56: 249-290 [Abstract] [Full Text]  
• Merx, M. W., Liehn, E. A., Janssens, U., Lutticken, R., Schrader, J., Hanrath, P., Weber, C. (2004). HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of Sepsis. Circulation 109: 2560-2565 [Abstract] [Full Text]  
• Schwarz, M. I., Albert, R. K. (2004). "Imitators" of the ARDS: Implications for Diagnosis and Treatment. Chest 125: 1530-1535 [Full Text]  
• Toyosawa, T., Suzuki, M., Kodama, K., Araki, S. (2004). Highly Purified Vitamin B2 Presents a Promising Therapeutic Strategy for Sepsis and Septic Shock. Infect. Immun. 72: 1820-1823 [Abstract] [Full Text]  
• Liang, E., Wong, Y. N., Allen, I., Kao, R., Marino, M., DiLea, C. (2003). Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function. J Clin Pharmacol 43: 1361-1369 [Abstract] [Full Text]  
• Fowler, R. A., Cook, D. J. (2003). The Arc of the Pulmonary Artery Catheter. JAMA 290: 2732-2734 [Full Text]  
• Yamada, T., Fujino, T., Yuhki, K.-i., Hara, A., Karibe, H., Takahata, O., Okada, Y., Xiao, C.-Y., Takayama, K., Kuriyama, S., Taniguchi, T., Shiokoshi, T., Ohsaki, Y., Kikuchi, K., Narumiya, S., Ushikubi, F. (2003). Thromboxane A2 Regulates Vascular Tone via Its Inhibitory Effect on the Expression of Inducible Nitric Oxide Synthase. Circulation 108: 2381-2386 [Abstract] [Full Text]  
• Kayman, H. (2003). Management of Fever: Making Evidence-Based Decisions. CLIN PEDIATR 42: 383-392  
• Aird, W. C. (2003). The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101: 3765-3777 [Abstract] [Full Text]  
• Nasraway, S. A. (2003). The Problems and Challenges of Immunotherapy in Sepsis. Chest 123 : 451S-459S [Abstract] [Full Text]  
• De Vriese, A. S. (2003). Prevention and Treatment of Acute Renal Failure in Sepsis. J. Am. Soc. Nephrol. 14: 792-805 [Full Text]  
• Hotchkiss, R. S., Karl, I. E. (2003). The Pathophysiology and Treatment of Sepsis. NEJM 348: 138-150 [Full Text]  
• Martin, G. S., Ely, E. W., Carroll, F. E., Bernard, G. R. (2002). Findings on the Portable Chest Radiograph Correlate With Fluid Balance in Critically Ill Patients. Chest 122: 2087-2095 [Abstract] [Full Text]  
• Hocherl, K., Dreher, F., Kurtz, A., Bucher, M. (2002). Cyclooxygenase-2 Inhibition Attenuates Lipopolysaccharide-Induced Cardiovascular Failure. Hypertension 40: 947-953 [Abstract] [Full Text]  
• Eichacker, P. Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., Natanson, C. (2002). Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis. Am. J. Respir. Crit. Care Med. 166: 1197-1205 [Abstract] [Full Text]  
• Cranshaw, J, Griffiths, M J D, Evans, T W (2002). The pulmonary physician in critical care c 9: Non-ventilatory strategies in ARDS. Thorax 57: 823-829 [Abstract] [Full Text]  
• Hebert, P. C., Cook, D. J., Wells, G., Marshall, J. (2002). The Design of Randomized Clinical Trials in Critically Ill Patients*. Chest 121: 1290-1300 [Abstract] [Full Text]  
• Thompson, B. T., Hayden, D., Matthay, M. A., Brower, R., Parsons, P. E. (2001). Clinicians' Approaches to Mechanical Ventilation in Acute Lung Injury and ARDS. Chest 120: 1622-1627 [Abstract] [Full Text]  
• Opal, S. M. (2001). Protein C Levels in Severe Sepsis. Chest 120: 699-701 [Full Text]  
• Yan, S. B., Helterbrand, J. D., Hartman, D. L., Wright, T. J., Bernard, G. R. (2001). Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis. Chest 120: 915-922 [Abstract] [Full Text]  
• Reddy, R. C., Chen, G. H., Tateda, K., Tsai, W. C., Phare, S. M., Mancuso, P., Peters-Golden, M., Standiford, T. J. (2001). Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L537-L543 [Abstract] [Full Text]  
• Landry, D. W., Oliver, J. A. (2001). The Pathogenesis of Vasodilatory Shock. NEJM 345: 588-595 [Full Text]  
• STUBER, F. (2001). Effects of Genomic Polymorphisms on the Course of Sepsis: Is There a Concept for Gene Therapy?. J. Am. Soc. Nephrol. 12: S60-S64 [Abstract] [Full Text]  
• Hasday, J. D., Bannerman, D., Sakarya, S., Cross, A. S., Singh, I. S., Howard, D., Drysdale, B.-E., Goldblum, S. E. (2001). Exposure to febrile temperature modifies endothelial cell response to tumor necrosis factor-{alpha}. J. Appl. Physiol. 90: 90-98 [Abstract] [Full Text]  
• MATUTE-BELLO, G., FREVERT, C. W., KAJIKAWA, O., SKERRETT, S. J., GOODMAN, R. B., PARK, D. R., MARTIN, T. R. (2001). Septic Shock and Acute Lung Injury in Rabbits with Peritonitis . Failure of the Neutrophil Response to Localized Infection. Am. J. Respir. Crit. Care Med. 163: 234-243 [Abstract] [Full Text]  
• Dubois, M.-J., Vincent, J.-L. (2000). Clinically-oriented therapies in sepsis: a review. Innate Immunity 6: 463-469 [Abstract]  
• Stefanec, T. (2000). Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease?. Chest 117: 841-854 [Abstract] [Full Text]  
• Plaisance, K. I., Mackowiak, P. A. (2000). Antipyretic Therapy: Physiologic Rationale, Diagnostic Implications, and Clinical Consequences. Arch Intern Med 160: 449-456 [Abstract] [Full Text]  
• Mayers, I., Johnson, D. (2000). Septic shock: treating more than just blood pressure. CMAJ 162: 369-370 [Full Text]  
• Eachempati, S. R., Hydo, L., Barie, P. S. (1999). Gender-Based Differences in Outcome in Patients With Sepsis. Arch Surg 134: 1342-1347 [Abstract] [Full Text]  
• PITTET, D., HARBARTH, S., SUTER, P. M., REINHART, K., LEIGHTON, A., BARKER, C., MACDONALD, F., ABRAHAM, E., the Ro 45-2081 Study Group, (1999). Impact of Immunomodulating Therapy on Morbidity in Patients with Severe Sepsis. Am. J. Respir. Crit. Care Med. 160: 852-857 [Abstract] [Full Text]  
• Ranieri, V. M., Suter, P. M., Tortorella, C., De Tullio, R., Dayer, J. M., Brienza, A., Bruno, F., Slutsky, A. S. (1999). Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With Acute Respiratory Distress Syndrome: A Randomized Controlled Trial. JAMA 282: 54-61 [Abstract] [Full Text]  
• Vandivier, R. W., Eidsath, A., Banks, S. M., Preas, H. L. II, Leighton, S. B., Godin, P. J., Suffredini, A. F., Danner, R. L. (1999). Down-Regulation of Nitric Oxide Production by Ibuprofen in Human Volunteers. J. Pharmacol. Exp. Ther. 289: 1398-1403 [Abstract] [Full Text]  
• Chernow, B. (1999). Variables Affecting Outcome in Critically Ill Patients. Chest 115 : 71S-76S [Abstract] [Full Text]  
• Wheeler, A. P., Bernard, G. R. (1999). Treating Patients with Severe Sepsis. NEJM 340: 207-214 [Full Text]  
• Steingrub, J. S. (1998). Novel Insights Into the Pathogenesis and Therapy of Circulatory Shock. SEMIN CARDIOTHORAC VASC ANESTH 2: 31-45 [Abstract]  
• Zimmerli, W., Widmer, A. F., Bernard, G. R., Wheeler, A. P., Christman, B. (1997). Ibuprofen in Patients with Sepsis. NEJM 337: 710-710 [Full Text]  
• Warren, H. S. (1997). Strategies for the Treatment of Sepsis. NEJM 336: 952-953 [Full Text]